雷莫芦单抗用于索拉非尼一线治疗后晚期肝细胞癌患者的二线治疗:随机III期REACH研究中以患者为中心的结局结果
REACH是一项III期安慰剂对照随机研究,评估雷莫芦单抗用于既往接受索拉非尼的晚期肝细胞癌患者。565例患者随机接受雷莫芦单抗或安慰剂,整体人群中FHSI-8、EQ-5D及体能状态恶化两组相似;基线AFP≥400 ng/mL患者中,雷莫芦单抗显著减少治疗结束时FHSI-8恶化(P=0.0381),FHSI-8症状恶化延迟(HR 0.690;P=0.054)与体能状态恶化延迟(HR 0.642;P=0.057)呈有利于雷莫芦单抗的趋势。
要点
- 整体人群中雷莫芦单抗与安慰剂在生活质量及体能状态恶化方面相似。
- 基线AFP≥400 ng/mL患者中雷莫芦单抗显著减少治疗结束时FHSI-8恶化(P=0.0381)。
- 该亚组中FHSI-8症状恶化延迟(HR 0.690;P=0.054)与体能状态恶化延迟(HR 0.642;P=0.057)呈有利趋势。
核心结论
- 雷莫芦单抗与生活质量未恶化相关;在基线AFP≥400 ng/mL患者中,观察到的显著生存获益与以患者为中心的结局获益趋势相伴随。
研究设计与样本
- III期安慰剂对照随机研究REACH,评估雷莫芦单抗用于既往接受索拉非尼的晚期肝细胞癌患者。
- 入组患者为晚期肝细胞癌、Child-Pugh A级、体能状态0或1且既往接受索拉非尼。
- 患者按1:1随机接受雷莫芦单抗8 mg/kg或安慰剂,于2周周期第1天给药。
- 共565例患者随机接受雷莫芦单抗或安慰剂。
- 分析意向治疗人群及预先规定的基线血清甲胎蛋白(AFP)≥400 ng/mL亚组。
主要发现
- FHSI-8与EQ-5D的依从性高且两组相似。
- 意向治疗人群中,雷莫芦单抗与安慰剂的FHSI-8、EQ-5D及体能状态恶化相似。
- 基线AFP≥400 ng/mL患者中,雷莫芦单抗较安慰剂显著减少治疗结束时FHSI-8恶化(P=0.0381)。
- 基线AFP≥400 ng/mL患者中,FHSI-8症状恶化延迟呈有利于雷莫芦单抗的趋势(HR 0.690;P=0.054)。
- 基线AFP≥400 ng/mL患者中,体能状态恶化延迟呈有利于雷莫芦单抗的趋势(HR 0.642;P=0.057)。
关键数值与推荐
- FHSI-8恶化定义为较基线下降≥3分。
- 体能状态恶化定义为变化≥2。
- 生活质量采用FHSI-8与EuroQoL(EQ-5D)评估,时间点为基线、第4、10、16周期及治疗结束。
- 体能状态评估时间点为基线、每周期及治疗结束。
局限性
- 基线AFP≥400 ng/mL患者中FHSI-8症状恶化延迟(HR 0.690;P=0.054)未达统计学显著。
- 基线AFP≥400 ng/mL患者中体能状态恶化延迟(HR 0.642;P=0.057)未达统计学显著。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To report patient-focused outcomes as measured by quality of life (QoL) and performance status (PS) in REACH, a phase III placebo-controlled randomised study, assessing ramucirumab in advanced hepatocellular carcinoma (HCC) patients who received prior sorafenib. METHODS: Eligible patients had advanced HCC, Child-Pugh A, PS 0 or 1 and prior sorafenib. Patients received ramucirumab (8 mg/kg) or placebo (1:1) on day 1 of a 2-week cycle. QoL was assessed by FACT Hepatobiliary Symptom Index (FHSI)-8 and EuroQoL (EQ-5D) at baseline; cycles 4, 10, and 16; and end of treatment. PS was assessed at baseline, each cycle, and end of treatment. Deterioration in FHSI-8 was defined as a ≥3-point decrease from baseline and PS deterioration was defined as a change of ≥2. Both intention-to-treat and pre-specified subgroup of patients with baseline serum alpha-fetoprotein (AFP) ≥400 ng/mL were assessed. RESULTS: There were 565 patients randomised to ramucirumab and placebo. Compliance with FHSI and EQ-5D was high and similar between groups. In the ITT population, deterioration in FHSI-8, EQ-5D, and PS was similar between ramucirumab and placebo. In patients with baseline AFP ≥400 ng/mL, ramucirumab significantly reduced deterioration in FHSI-8 at the end of treatment compared with placebo (P = 0.0381), and there was a trend towards a delay in the deterioration of symptoms in FHSI-8 (HR 0.690; P = 0.054) and PS (HR 0.642; P = 0.057) in favour of ramucirumab. CONCLUSIONS: We report one of the most comprehensive data sets of QoL and symptom burden in patients undergoing systemic therapy for advanced HCC. Ramucirumab was associated with no worsening of QoL. In patients with baseline AFP ≥400 ng/mL, the significant survival benefit observed in patients treated with ramucirumab was coupled with a trend in patient-focused outcome benefits. CLINICAL TRIAL REGISTRATION: NCT01140347.
引用
- Chau I, Peck-Radosavljevic M, Borg C, et al. Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study. Eur J Cancer. 2017. PMID: 28591675. doi:10.1016/j.ejca.2017.05.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。